Novel evidence‐based systemic lupus erythematosus responder index
Arthritis Care & Research · 15.09.2009 · 61 (9) · 1143-1151
DOI: 10.1002/art.24698 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 27.08.2009. Verfasst von Richard A Furie und 11 weiteren Autor:innen. Beteiligte Einrichtung: North Shore-Long Island Jewish Health System, Lake Success, New York, USA. furie@nshs.edu. Hauptthemen laut MEDLINE: Endpoint Determination, Evidence-Based Medicine, Health Status Indicators, Severity of Illness Index. Die Arbeit wurde bisher 439-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCRR NIH HHS.
Abstract (Originalsprache)
Objective
To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials.
Methods
Data from a randomized, double‐blind, placebo‐controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56‐week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti–double‐stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI.
Results
SRI response is defined as 1) a ≥4‐point reduction in SELENA–SLEDAI score, 2) no new BILAG A or no more than 1 new BILAG B domain score, and 3) no deterioration from baseline in the physician's global assessment by ≥0.3 points. In serologically active patients, the addition of belimumab to SOC resulted in a response in 46% of patients at week 52 compared with 29% of the placebo patients ( P = 0.006). SRI responses were independent of baseline autoantibody subtype.
Conclusion
This evidence‐based evaluation of a large randomized, placebo‐controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- North Shore-Long Island Jewish Health System, Lake Success, New York, USA. furie@nshs.edu
Förderung
- NCRR NIH HHS
Zitieren
APA
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., Zhong, Z. J., & Freimuth, W. W. (2009). Novel evidence‐based systemic lupus erythematosus responder index. Arthritis Care & Research, 61(9), 1143-1151. https://doi.org/10.1002/art.24698
Vancouver
Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence‐based systemic lupus erythematosus responder index. Arthritis Care & Research. 2009;61(9):1143-1151. doi:10.1002/art.24698
BibTeX
@article{Furie2009,
author = {Furie, Richard A and Petri, Michelle A and Wallace, Daniel J and Ginzler, Ellen M and Merrill, Joan T and Stohl, William and Chatham, W Winn and Strand, Vibeke and Weinstein, Arthur and Chevrier, Marc R and Zhong, Z John and Freimuth, William W},
title = {Novel evidence‐based systemic lupus erythematosus responder index},
journal = {Arthritis Care & Research},
year = {2009},
volume = {61},
number = {9},
pages = {1143--1151},
doi = {10.1002/art.24698}
}
EUVIMED